CPRX vs CRNX

Catalyst Pharmaceuticals, Inc. vs Crinetics Pharmaceuticals, Inc. — Valuation Comparison 2026

CPRX

Pharmaceutical Preparations
Catalyst Pharmaceuticals, Inc.
Quality
10.0
out of 10
Value Trap
18
SAFE
Price
$31.23
Last close
Models
13/13
Active
VS

CRNX

Pharmaceutical Preparations
Crinetics Pharmaceuticals, Inc.
Quality
6.1
out of 10
Value Trap
24
SAFE
Price
$35.55
Last close
Models
12/13
Active

Model-by-Model Comparison

ModelType CPRX Fair ValueCPRX Upside CRNX Fair ValueCRNX Upside
Bayesian DCF Intrinsic $31.62 +1.2% $11.21 -68.5%
Earnings Power Value Intrinsic $18.57 -40.5% $1.27 -96.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CPRX vs CRNX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CPRX vs CRNX — Which Stock Is More Undervalued?

CPRX scores higher with a 10.0/10 quality rating vs CRNX's 6.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Catalyst Pharmaceuticals, Inc. (CPRX) and Crinetics Pharmaceuticals, Inc. (CRNX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CPRX currently trades at $31.23 with a QOC of 10.0/10, while CRNX trades at $35.55 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).